Agol V I, Grachev V P, Drozdov S G, Kolesnikova M S, Kozlov V G, Ralph N M, Romanova L I, Tolskaya E A, Tyufanov A V, Viktorova E G
Virology. 1984 Jul 15;136(1):41-55. doi: 10.1016/0042-6822(84)90246-0.
An attempt was made to map, in a general way, the region of the poliovirus genome that is responsible for the neurovirulent and attenuated phenotypes of different virus strains. A set of four recombinants was investigated, one described previously (E. A. Tolskaya, L. I. Romanova, M. S. Kolesnikova, and V. I. Agol, 1983, Virology 124, 121-132) and three obtained in the present work with the following genetic structure: a 5' end-adjacent segment of the genome derived from either a virulent strain (452/62 3D), or from an attenuated strain (Leon-2) of poliovirus type 3, the remaining RNA sequences being derived from either a virulent strain (Mgr), or an attenuated strain (LSc-gr3) of poliovirus type 1. The crossover points in the recombinant genomes were centrally located, somewhere between the gene(s) that determines antigenic specificity of the virus and the locus that determines resistance of virus multiplication to low doses of guanidine. The recombinant nature of the newly selected clones was definitively established by mapping RNase T1 oligonucleotides of their genome. The recombinants were characterized with respect to their ability to produce infectious progeny and synthesize viral RNA at an elevated temperature. Neurovirulence of the recombinants was assayed by intracerebral inoculation of monkeys. Irrespective of the origin of the 3' end-adjacent segment of the genome, the recombinants that inherited the 5' end-adjacent segment from the neurovirulent parent were neurovirulent, whereas the recombinants with the 5' end-adjacent segment derived from the attenuated parent were not. The results suggest that the major determinants of neurovirulence of these recombinants (and by inference, of their parental viruses) reside in the 5' end-adjacent segment of poliovirus genome, known to code for capsid proteins.
研究人员试图大致定位脊髓灰质炎病毒基因组中与不同病毒株的神经毒力和减毒表型相关的区域。研究了一组四个重组体,其中一个先前已有描述(E. A. 托尔斯卡娅、L. I. 罗曼诺娃、M. S. 科列斯尼科娃和V. I. 阿戈尔,1983年,《病毒学》124卷,121 - 132页),另外三个是在本研究中获得的,具有以下遗传结构:基因组5' 端相邻片段要么源自3型脊髓灰质炎病毒的强毒株(452/62 3D),要么源自减毒株(莱昂 - 2),其余RNA序列要么源自1型脊髓灰质炎病毒的强毒株(Mgr),要么源自减毒株(LSc - gr3)。重组基因组中的交叉点位于中心位置,在决定病毒抗原特异性的基因和决定病毒增殖对低剂量胍抗性的位点之间的某个位置。通过对新选择克隆的基因组进行核糖核酸酶T1寡核苷酸图谱分析,明确确定了它们的重组性质。对这些重组体在高温下产生感染性后代和合成病毒RNA的能力进行了表征。通过对猴子进行脑内接种来检测重组体的神经毒力。无论基因组3' 端相邻片段的来源如何,从神经毒力亲本继承5' 端相邻片段的重组体具有神经毒力,而5' 端相邻片段源自减毒亲本的重组体则没有。结果表明,这些重组体(以及由此推断其亲本病毒)神经毒力的主要决定因素位于脊髓灰质炎病毒基因组的5' 端相邻片段,已知该片段编码衣壳蛋白。